Bachmann–Bupp Syndrome (BABS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

 Bachmann–Bupp syndrome (BABS) is an autosomal dominant genetic disorder caused by heterozygous de novo gain-of function pathogenic variants in the ornithine decarboxylase 1 (ODC1) gene located on chromosome 2p25.1. These variants result in increased polyamines, causing abnormalities of functions such as angiogenesis, carcinogenesis, and embryogenesis. Currently, there are nine humans reported having ODC1 pathogenic variants. Features which are shared amongst these individuals include polyhydramnios, broad forehead/macrocephaly, neuroimaging abnormalities with no particular pattern, global developmental delay, cryptorchidism in male patients, and muscular hypotonia. The patient presented at 11 months of age with near-total alopecia of the scalp, eyebrows, eyelashes and curved, brittle fingernails. Around age one year, she started developing pustules and cysts on the posterior scalp and back. Five larger lesions became erythematous and tender, resulting in rupture and ultimately requiring excision.

Thelansis’s “Bachmann–Bupp Syndrome (BABS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Bachmann–Bupp Syndrome (BABS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Bachmann–Bupp Syndrome (BABS) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Bachmann–Bupp Syndrome (BABS) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Bachmann–Bupp Syndrome (BABS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032